Vaughn Himes - Seagen EVP
| SGENDelisted Stock | USD 228.74 0.19 0.08% |
EVP
Dr. Vaughn B. Himes, Ph.D. is Chief Technical Officer of Seattle Genetics, Inc., since August 2016. Dr. Himes joined Seattle Genetics as Executive Vice President, Technical Operations in April 2009 and served as our Executive Vice President, Technical Operations and Process Science from July 2012 until August 2016. Previously, Dr. Himes was with ZymoGenetics, Inc. from November 2005 to March 2009, most recently as Senior Vice President, Technical Operations where his responsibilities included commercial and clinical manufacturing, supply chain and logistics, quality control and process development. From March 2003 to October 2005, he was Vice President, Manufacturing at Corixa, Inc. Prior to that, he held Vice President positions in manufacturing and development at Targeted Genetics and Genovo, Inc since 2016.
| Age | 62 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Phone | 425 527 4000 |
| Web | https://www.seagen.com |
Seagen Management Efficiency
The company has return on total asset (ROA) of (0.1294) % which means that it has lost $0.1294 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2793) %, meaning that it created substantial loss on money invested by shareholders. Seagen's management efficiency ratios could be used to measure how well Seagen manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 43.47 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Seagen Inc has a current ratio of 4.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Seagen until it has trouble settling it off, either with new capital or with free cash flow. So, Seagen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Seagen Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Seagen to invest in growth at high rates of return. When we think about Seagen's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 3 records | EVP Age | ||
| Reid Huber | Incyte | 45 | |
| Robert Baffi | Biomarin Pharmaceutical | 62 | |
| Peter Lamb | Exelixis | 63 | |
Management Performance
| Return On Equity | -0.28 | |||
| Return On Asset | -0.13 |
Seagen Inc Leadership Team
Elected by the shareholders, the Seagen's board of directors comprises two types of representatives: Seagen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Seagen. The board's role is to monitor Seagen's management team and ensure that shareholders' interests are well served. Seagen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Seagen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roger Dansey, Chief Medical Officer | ||
| Vaughn Himes, Executive VP of Process Sciences and Technical Operations | ||
| Daniel Welch, Independent Director | ||
| Felix Baker, Lead Independent Director | ||
| Nancy Simonian, Independent Director | ||
| Peggy Pinkston, IR Contact Officer | ||
| Charles Romp, Ex US | ||
| MS JD, Chief Officer | ||
| Darren Cline, Executive Vice President - Commercial | ||
| Eric Dobmeier, COO, Corporate Secretary | ||
| Todd Simpson, CFO and Principal Accounting Officer | ||
| Pinkston Peggy, Senior Director - Corporate Communications | ||
| David Gryska, Independent Director | ||
| David Caouette, VP Communications | ||
| Srinivas Akkaraju, Independent Director | ||
| Alpna Seth, Director | ||
| Matt Skelton, VP Marketing | ||
| Marc Lippman, Independent Director | ||
| Jonathan Drachman, Chief Medical Officer and Executive Vice President Research and Development | ||
| Jean Liu, Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary | ||
| Robert Lechleider, Senior Vice President - Clinical Development | ||
| Christopher Pawlowicz, Ex HR | ||
| Clay Siegall, Co-Founder, Chairman, CEO and Pres | ||
| Robin Taylor, Chief Commercial Officer | ||
| Dennis Benjamin, Senior Vice President - Translational Research | ||
| Roger MD, Pres RD | ||
| John Orwin, Director | ||
| John McLaughlin, Independent Director |
Seagen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Seagen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.28 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.33) % | |||
| Operating Margin | (0.35) % | |||
| Current Valuation | 42.06 B | |||
| Shares Outstanding | 188.66 M | |||
| Shares Owned By Insiders | 0.81 % | |||
| Shares Owned By Institutions | 88.82 % | |||
| Number Of Shares Shorted | 9.58 M | |||
| Price To Earning | 32.75 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Seagen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Seagen's short interest history, or implied volatility extrapolated from Seagen options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the Seagen Inc information on this page should be used as a complementary analysis to other Seagen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in Seagen Stock
If you are still planning to invest in Seagen Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Seagen's history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |